

10/26/2012

CURRICULUM VITAE

MICHELLE A. LALLY, M.D., M.Sc.

Business Address: The Miriam Hospital
164 Summit Avenue
Providence, RI 02906

Telephone: 401-793-4710
Facsimile: 401-793-4709
E-Mail: mlally@lifespan.org

EDUCATION

1989 B.S. *Biochemistry/Philosophy, magna cum laude*
Boston College
Chestnut Hill, MA,
1993 M.D. University of Virginia School of Medicine
Charlottesville, VA
1999 M.Sc. *Epidemiology*
Harvard School of Public Health
Boston, MA

POST GRADUATE TRAINING

1993 - 1994	Internship in Internal Medicine	New England Deaconess Hospital Harvard Medical School Boston, MA
1994 - 1996	Residency in Internal Medicine	New England Deaconess Hospital Harvard Medical School Boston, MA
1996 - 1997	Clinical Fellow in Infectious Diseases	New England Deaconess Hospital Harvard Medical School Boston, MA
1997 - 1998	Research Fellow in Infectious Diseases	Beth Israel Deaconess Medical Center/ Harvard Medical School Boston, MA
2008 - 2009	Invited Attendee Physician Leadership Academy <u><i>Elevating Individual Leadership Skills</i></u>	Rhode Island Hospital Providence, RI One-Year On-Site Curriculum <i>through</i> The Advisory Board Company Washington, DC

POST GRADUATE HONORS AND AWARDS

- 2000 - 2002 Preceptorship Award: “An outstanding teacher in medicine”
The Miriam Hospital, and Brown University
- July, 2002 The Dean’s Teaching Excellence Award: “In recognition of exemplary teaching in
Bio 282 Infectious Disease Pathophysiology” small group sessions
Brown Medical School
- June, 2007 The Dean’s Teaching Excellence Award: “In recognition of exemplary teaching in
351 Infectious Disease Pathophysiology” small group sessions
The Warren Alpert Medical School of Brown University
- Sept. 2011 - Lifespan Executive Mentorship Program
Aug. 2012

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

- 1996 Diplomate Internal Medicine , American Board of Internal Medicine
- 1998 Diplomate Infectious Diseases, American Board of Internal Medicine
- 1998 - Rhode Island Board of Medical Licensure and Discipline
- 2009- Massachusetts Board of Registration in Medicine
- 2009 Diplomate, Infectious Diseases, American Board of Internal Medicine

ACADEMIC APPOINTMENTS

- 1993 - 1998 Clinical Fellow in Medicine
Harvard Medical School
Boston, MA
- 1999 - 2009 Assistant Professor of Medicine
Brown University School of Medicine
Providence, RI
- 2009- Associate Professor of Medicine
Alpert Medical School of Brown University
Providence, RI
- 2010- Medical Director
Rhode Island Clinical Research Center
Providence, RI
- 2010- Co-Chair
Prevention CORE
Lifespan/Tufts/Brown Center for AIDS Research (CFAR)
- 2011- Director
Brown University AIDS Program (BRUNAP)
- 2011- Elected Chair
Community Prevention Leadership Group (CPLG) of the
Adolescent Medicine Trials Network (ATN)
- 2011 - Associate Professor of Health Services, Policy and Practice
Alpert Medical School of Brown University
Providence, RI
- 2012 - Associate Director
Brown University AIDS Center

HOSPITAL APPOINTMENTS

- 1993 - 1996 Residency in Internal Medicine
New England Deaconess Hospital/Harvard Medical School
Boston, MA
- 1996 - 1998 Fellow in Infectious Disease
New England Deaconess Hospital/Harvard Medical School
Boston, MA
- 1998 - Attending Physician
The Miriam Hospital
Providence, RI
- 1998 - Medical Staff Association
The Miriam Hospital
Providence, RI
- 1999 - Attending Physician
Rhode Island Hospital
Providence, RI

OTHER APPOINTMENTS

- 1996 - 1998 Clinical Trials Physician
Adult Clinical Trials Group
Beth Israel Deaconess Medical Center
Study physician involved with participant enrollment and study physicals for the HIV Adult Clinical Trials Group, investigating optimal therapeutics for persons with HIV.
- 1999 - 2001 Clinical Trials Physician
HIV Vaccine Clinical Trials Group
Miriam Hospital/Brown University
Principal Investigator for two separate HIV preventative vaccine clinical trials. These were VAX004, the only Phase III trials of an HIV vaccine candidate conducted domestically, to date, and Merck 007, a Phase I trial of Merck's original candidate HIV vaccine.
- 2001 - Director
HIV Vaccine Clinical Trials Unit
The Miriam Hospital/Brown University
A dedicated HIV Vaccine Clinical Trials Unit has been established with specific clinical and regulatory staff. Michelle Lally is the Director of the unit, oversees all staff, and is the site Principal Investigator for the multi-center trials that are conducted here. These trials include twelve sponsored by the NIH/HIV Vaccine Trials Unit (HVTN) (HVTN-040, 203, 042, 044, 048, 049, 050, 052, 057, 063, 204, 403) and six HIV vaccine trials sponsored by Merck (Merck-007, 016, 019, 022, 001, 027). Additionally, two Merck-sponsored HPV vaccine trials are being conducted in this unit.
- 2002 -2006 Invited Member, HIV Vaccine Trials Network Phase III Committee
The Phase III Committee was involved with all aspects of high-risk participant enrollment criteria, recruitment strategies, and overall study design. This

- Committee was phased out with many responsibilities then assumed by the Protocol Committee as well as separate specific working groups.*
- 2002 -2010 Invited Member, Chiron/HVTN HIV Vaccine Development Team
Chiron had committed to evaluating its candidate HIV vaccine through clinical trials conducted by the HVTN. It was the responsibility of the Development Team to design these trials.
- 2002 -2010 Protocol Co-Chair, HVTN 049: A Phase I Clinical Trial to evaluate the Safety and Immunogenicity of a Clade B Gag DNA/PLG and Env DNA/PLG Microparticles Prime with a Clade B Recombinant, Oligometric GP140/MF59 Adjuvant Boost in Health, HIV-1 Uninfected Adult Participants (Chiron candidate HIV vaccine).
First Phase I trial using Chiron's candidate HIV vaccine. Descriptive manuscript has been published.
- 2002 - Member, HIV Vaccine Trials Network Adolescent Working Group
Working group led by the HVTN that includes members from several other NIH-sponsored networks and distinguished organizations who have an interest in adolescents and their participation in HIV vaccine clinical trials.
- 2002 - Manuscript Reviewer, Clinical Infectious Diseases
2006- Member, HVTN Adolescent Trials Coordinating Group
Five-member committee of HVTN members, responsible for developing and implementing adolescent HIV vaccine trials within the HVTN
- 2006- HIV Vaccine Trials Network (HVTN) Adolescent Representative and Liaison
As a lead HVTN investigator for adolescent issues, asked to serve as the liaison to other NIH-sponsored networks, the Adolescent Medicine Trials Network (ATN) the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), and to interface with Partners for Aids Vaccine Enterprise (PAVE) and its members (Department of Defense, International Aids Vaccine Initiative (IAVI), the Centers for Disease Control (CDC) in an effort to facilitate the development of adolescent HIV vaccine trials.
- 2006 - 2011 Invited Member, HVTN Protocol Committee
Committee responsible for review and approval of all trials proposed to the HVTN
- 2006 - Invited Member, HVTN Representative, The Vaccine/Immuno-based Therapy Scientific Committee (Vaccine SC) of the International, Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
The Vaccine Scientific Committee is one of the five scientific leadership committees within the IMPAACT Network
- 2006 - 2007 Invited Co-Chair, NIH Working Group on HIV Viral Load Detection: Rapid Assays and the use of Dried Blood Spots
Working group established by the NIH to evaluate the ideal specifications and characteristics for a rapid HIV viral load assay. Uses would include not only diagnosis among HIV vaccine recipients, but also infant diagnosis and HIV therapeutic monitoring. Led to summer conference in 2007, and release of RFP in 2008.
- 2006 - 2007 Protocol Team Member, HVTN Representative: IMPAACT P1067 Phase I/II Trial to Evaluate the Safety, Tolerability, Immunogenicity and Optimal Dosing of the MRK Ad5-HIV-1 gag/pol/nef Trivalent Vaccine in HIV-Exposed Newborns: An

International Study of the International Maternal Pediatric Adolescent AIDS
Clinical Trials Group

*Asked to participate in the development of this first planned study of MRK
candidate vaccine in infants. Study will not go forward based on STEP trial
results which demonstrated, as of 9/07, that this candidate vaccine is not
efficacious.*

2006 -2007 HVTN Protocol Co-Chair, HVTN-075: Safety and Immunogenicity of the VRC
Candidate Vaccine among Adolescents in the United States

*This was the first proposed domestic trial of an HIV vaccine candidate among
Adolescents. This trial was led by the HVTN and would be conducted in
collaboration with the ATN and IMPAACT. The three co-chairs of this protocol
were representatives from the HVTN, ATN, and IMPAACT networks respectively.
This study was stopped as the results of the STEP trial being negative as this
candidate vaccine is similar to the one tested in the STEP trial.*

2006 - Manuscript Reviewer, American Journal of Preventive Medicine

2007 - Faculty Member

Sylvie Ratelle STD/HIV Prevention Training Center of New England

2007 - Manuscript reviewer, Journal of Adolescent Health

2008 - Member, Adolescent Medicine Leadership Group of the Adolescent Trials
Network (ATN)

*Asked to support the Adolescent Medicine Leadership Group of the NIH-funded
ATN in the formulation of hypotheses and review of proposals submitted to the
Network for scientific merit and feasibility. The primary mission of the ATN is to
explore promising behavioral, microbicial, prophylactic, therapeutic, and
vaccine modalities in HIV-infected and HIV at-risk adolescents, age 12
through 24.*

2008 - 2010 Director, University Medicine Foundation
Travel and Vaccination Clinic

2008, 2009 Grant Peer Reviewer

Special Emphasis Panel

Centers for Disease Control and Prevention (CDC)

Grants for Public Health Research

2010- Director, University Medicine Foundation

Vaccination Clinic

2010 Grant Peer Reviewer

NIH Special Emphasis Panel

Informed Decision-Making in Young Adolescents at Risk for HIV/AIDS (R01)

RFA Number: RFA-NR-10-008

2010 NIH Grant Reviewer

NINR Special Emphasis Panel

Adolescent Risk for HIV

2010 - Manuscript Reviewer, Journal of the American Medical Association

2011 - Co-Investigator, Adolescent Trials Network Unit

Fenway Institute, Boston, MA

- 2011 - Invited Member
Lifespan Research Advisory Committee (RAC)
- 2011 - Director, Brown AIDS Program (BRUNAP)
- 2011- Invited Member
Advisory Board
Sylvie Ratelle STD/HIV Prevention Training Center of New England
- 2011- Invited Member, HIV Advisory Council CT/RI Public Health Training Center
- 2012 Invited Member
AIDS Vaccine 2012 Scientific Organizing Committee
International Committee charged with helping to set the scientific agenda for Global HIV Vaccine Enterprise and AIDS Vaccine 2012 meeting.
- 2012 Planning Committee
Women and HIV
The Warren Alpert Medical School, Brown University, and the Brown University AIDS Program

HOSPITAL COMMITTEES

- 1997 - 1998 Beth Israel Deaconess Medical Center
Quality Improvement Committee
- 2000 - Infectious Diseases Fellowship Committee
The Miriam Hospital
- 2004 Search Committee
Renal Division Clinical Assistant Professor
The Miriam Hospital
- 2005 Search Committee
Infectious Disease Division Clinical Assistant Professor
The Miriam Hospital
- 2005 Lifespan Developmental Grant Reviewer
- 2008 Invited Member
Lifespan Task Force on Clinical Trials Billing Practices

UNIVERSITY COMMITTEES

- 1992 - 1993 University of Virginia School of Medicine
Admissions Committee
- 2003 Brown's Annual Hospital Research Celebration
Judge - Young Investigator Award Competition
- 2006 -2009 Medical Faculty Executive Committee
The Warren Alpert Medical School of Brown University
- 2012 Department of Medicine Promotions Committee

MEMBERSHIP IN SOCIETIES

- 2000 - 2004 American Society of Addiction Medicine
- 2000 - 2004 American Medical Association
- 2000 - Infectious Diseases Society of America
- 2001 - 2010 American College of Physicians - American Society of Internal Medicine

2002 - Rhode Island Medical Society
2006 - Society for Adolescent Medicine

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Sakoulas G, Tritos N, Lally MA, Wanke C, Hartzband P. Hypercalcemia in an AIDS patient treated with growth hormone. *AIDS* 11:1353-56, 1997.
2. Harris A, Lally MA, Albrecht M. Legionella bozemanii pneumonia in three patients with HIV infection. *Clin Infect Dis* 27(1):97-9, 1998. (Free full text)
3. Spaulding AC, Lally MA, Rich JD, Dietrich DT. Hepatitis B & C in the context of HIV disease: implications for incarcerated populations. *AIDS Reader* 9(7):481-91, 1999.
4. Farley JL, Adelson Mitty J, Lally MA, Burzynski JN, Tashima K, Rich JD, Cu-Uvin S, Spaulding A, Normandie L, Snead M, Flanigan T. Comprehensive medical care among HIV-positive incarcerated women: the Rhode Island experience. *J Women's Health Gender-Based Med* 9(1):51-6, 2000.
5. Pugatch DL, Levesque BG, Greene S, Strong L, Flanigan T, Lally MA. HIV testing in the setting of inpatient acute substance abuse treatment. *Am J Drug Alcohol Abuse* 27(3):491-99, 2001.
6. Pugatch DL, Levesque BG, Lally MA, Reinert SE, Filippone WJ, Flanigan TP, Brown LK, Combs C. HIV testing among young adults and older adolescents in the setting of acute substance abuse treatment. *J Acquir Immune Defic Syndr* 27(2):135-42, 2001.
7. Pugatch DL, Strong L, Ramratnam M, Levesque BG, Lally MA, Combs C, Patterson D, Brown L. HIV risk behaviors in young adolescent and young adult substance users undergoing treatment. *J HIV/AIDS Prev Ed Adolesc Child* 4(4):43-54, 2001.
8. Rich JD, Hou J, Charuvastra A, Towe C, Lally MA, Spaulding A, Bandy U, Donnelly E, Rompalo A. Risk factors for syphilis among incarcerated women in Rhode Island. *AIDS Pt Care STDs* 15(11):581-85, November 2001.
9. Beckwith CG*, Lally MA. Missed opportunities for HIV screening: patients diagnosed with HIV in Rhode Island hospital over a two-year period. *RI Med Health* 85(11):332, 2002 (*Curt Beckwith, Infectious Diseases Fellow).
10. Lally MA, Alvarez S, MacNevin R, Cenedella C, DiSpigno M, Harwell JI, Pugatch D, Flanigan T. Acceptability of sexually transmitted infection screening among women in short term substance abuse treatment. *Sex Trans Dis* 29(12):752-5, 2002.
11. DeGroot AS, Bishop EA, Khan B, Lally MA, Marcon L, Franco J, Mayer KH, Carpenter CCJ, Martin M. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. *Methods* 34(4):476-87, 2004.
12. Flynn, MN, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MH, Gilbert PF, Hudgens MG, Metch BJ, Self SG, Berman PW, Francis DP, Gurwith M, Heyward WL, Jobes DV, Peterson ML, Popovic V, Sinangil FM, Gurwith M, Jobes DV, Peterson ML, Berman PW, Francis DP, Heyward WL, Gilbert PB, Hudgens MG, Self SG, Adamczyk A, Baker RL, Brand D, Brown SJ, Buchbinder S, Buggy BP, Cade J, Caldwell MC, Celum C, Creticos C, Coutinho RA, Lindenburg K, Daly P, DeJesus E, Di-Carlo R, Fenstersheib M, Flynn N, Forthal D, Gripshover B, Gorse GJ, Belshe R, Grossman H, Henry K, Hewitt RG, Hogg R, Jacobson JM, Jemsek J, Judson F, Kahn JO, Keefer MC, Kessler H, Koblin B, Kostman J, Lally MA, Logue K, Marmor M, McKinsey D, Miskin BM, Morales JO, Mulligan MJ, Myers RA, Novak R, Para M, Piliero P, Poblete R, Rhame F, Riddler S, Richter RW, Sampson JH, Sands M, Santiago S, Shikuma C,

- Somero MS, Thomas E, Thompson M, Tying SK, Vincelette J, Vrooman PS, Yango BG, rpg 120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *J Infect Dis* 191(5):654-665, 2005.
13. Lally MA, MacNevin R, Sergie Z, Hitt R, DiSpigno M, Cenedella C, Stein MD. A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center. *AIDS Pt Care STDs* 19(5):298-306, 2005. PMC1852463
 14. Lally MA, Gaitanis MD, Vallabhaneni S, Reinert S, Mayer K, Zimet G, Rich JD. Willingness to receive an HIV vaccine among incarcerated persons. *Prev Med* 43(5):402-405, 2006. PMC3249390
 15. Tedeschi SK*, Bonney LE*, Manalo R, Mayer KH, Shepardson S, Rich JD, Lally MA. Vaccination in juvenile correctional facilities: state practices, hepatitis B, and the impact on anticipated sexually transmitted infection vaccines. *Pub Health Rep* 122(1):44-8, 2007. PMC1802118 (*Sara Tedeschi, Pre-Med Research Assistant; Loida Bonney, T32 Research Fellow).
 16. Beckwith CG, Atunah-Jay S, Cohen J, Macalino G, Poshkus M, Rich JD, Flanigan TP, Lally MA. Feasibility and acceptability of rapid HIV testing in jail. *AIDS Pt Care STDs* 21(1):41-7, 2007.
 17. Beckwith CG, Cohen J, Shannon C, Raz L, Rich JD, Lally MA. HIV testing experiences among male and female inmates in Rhode Island. *AIDS Reader* 17(9):459-64, 2007.
 18. Lally MA, Montstream-Quas S, Tanaka S, Tedeschi S, Morrow K. A qualitative study among injection drug using women in Rhode Island: attitudes toward testing, treatment, and vaccination for hepatitis and HIV. *AIDS Pt Care STDs* 22(1):53-64, 2008. NIHMSID 345198 PMC3291495
 19. Quirk EK, Mogg R, Brown DD, Lally MA, Mehrotra DV, DiNubile MJ, Robertson MN. HIV seroconversion without infection after receipt of adenovirus-vectored HIV-1 vaccines. *Clin Infect Dis* 47(12):1593-9, 2008. (Free full text)
 20. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally MA, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E, for the Merck V520-016 Study Group. Safety and immunogenicity of a replication-incompetent adenovirus type-5 HIV-1 Clade B gag/pol/nef vaccine in healthy adults. *Clin Infect Dis* 46(11):1769-81, 2008. (Free full text)
 21. Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Pridd FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV, for the Merck V520-007/012 Study Groups. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 Clade B gag vaccines in healthy adults. *AIDS Res Hum Retroviruses* 25(1):103-14, 2009. PMC3256563
 22. Henderson CE, Rich JD, Lally MA. HPV vaccination practices among juvenile justice facilities in the United States *J Adolesc Health* 46(5):495-8, 2010. PMC2927822
 23. Rudy BJ, Kapogiannis BG, Lally MA, Gray GE, Bekker LG, Krogstad P, McGowan I. Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. *J Acquir Immune Defic Syndr* 54 Suppl 1:S31-42, 2010. PMC2912697

24. Churchyard GJ, Morgan C, Adams E, Hural J, Graham BS, Moodie Z, Grove D, ray G, Bekker LG, McElrath MJ, Tomaras GD, Goepfert P, Kalams S, Baden LR, **Lally MA**, Dolin R, Blattner W, Kalichman A, Figueroa JP, Paper J, Schechter M, Defawe O, DeRosa SC, Montefiori DC, Nabel GJ, Corey L, Keefer MC. A phase IIA study of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 boost in healthy adults: a randomized clinical trial (HVTN204). *PLoS ONE* 03 Aug 2011. PMC3152265
25. Spearman P, **Lally MA**, Elizaga M, Ontefiori D, Tomaras GD, McElrath MJ, Hural J, DeRosa SC, Sata A, Huang Y, Frey SE, Sato P, Donnelly J, Barnett S, Corey LJ, and the **HIV Vaccine Trials Network of NIAID**. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. *J Infect Dis* 203(8):1165-73, 2011. PMC3068023
26. Nugent NR, **Lally M**, Brown L, Knopik V, McGeary J. OPRMI and diagnosis related posttraumatic stress disorder in binge-drinking patients living with HIV. *AIDS and Behavior* [Epub 12/6/11].
27. Ma M, Kibler JL, Vigil-Otero A, Sarpong D, **Lally M**, Mayer KH. Correlates of Willingness to Participate in Microbicide Research among African Americans. *J Health Psychology* [epub 2/24/12] PMID22366042
28. Nunn A , Cornwall A, Chute N, Sanders J, Thomas G, James G, **Lally M**, Trooskin S, Flanigan T. Keeping the Faith: African American Faith Leaders' Perspectives and Recommendations for Reducing Racial Disparities in HIV/AIDS Infection. *PLoS ONE*, 7(5):e36172, 2012. [Epub 5/16/12]. PMC3353968
29. Li M, Aliotta JM, Asara JM, Tucker L, Quesenberry P, **Lally M**, Ramratnam B, Quantitative proteomic analysis of exosomes from HIV-1 infected lymphocytic cells. *PROTEOMICS*, 12(13):2203-2211, 2012. PMID 22807456

OTHE PEER-REVIEWED PUBLICATIONS

1. Mylonakis E, Paliou M, **Lally MA**, Flanigan TP, Rich, JD. Laboratory Testing for Infection with the Human Immunodeficiency Virus: Established and Novel Approaches. *Am J Med* 109(7):568-76, 2000 (review).
2. Beckwith CG*, **Lally MA**, Flanigan TP. Routine HIV Testing among Inpatients. *Arch Intern Med* 162(19):2252-3, 2002 (letter to the editor). (*Curt Beckwith, Infectious Diseases Fellow).
3. Rich JD, Ching CG, **Lally MA**, Gaitanis MM, Schwartzapfel B, Charuvastra A, Beckwith CG*, Flanigan, TP. A review of the case for hepatitis B vaccination of high-risk adults. *Am J Med* 114(4):316-8, 2003.
4. Simmons E, **Lally MA**, Flanigan TP. Routine, not risk-based, human immunodeficiency virus testing is the way to go. *J Infect Dis* 187(6):1024, 2003 (letter to the editor). (Free full text)
5. Beckwith CG*, Simmons E, **Lally MA**, Flanigan TP. Testing for HIV infection: should it be routine? *Res Staff Phys* 50(4):9-15, 2004 (featured article). (*Curt Beckwith, Infectious Diseases Fellow).
6. Bonney LE*, **Lally, MA**, Williams D, Stein MD, Flanigan TP. Where to begin human papillomavirus vaccination. *Lancet Infect Dis* 6(7):389-390, 2006 (letter to the editor). (*Loida Bonney, T32 Research Fellow).

7. Lally MA, Lemei KD, Bonney LE, Zimet GD. HPV vaccination: an opportune time for HIV testing. (Letter to the editor) *J Adolesc Health* 40:384-5, 2007.
8. Lally MA, Lemei KD, Mayer K. HIV vaccine update: recent developments and current trials. *Med Health RI* 90(10):318-20, 2007 (review).

OTHER NON PEER-REVIEWED PUBLICATIONS

1. Pugatch DL, Lally MA, Combs C, Rich JD, D'Angelo L, Brown LK. Intranasal heroin use and HIV prevention: opportunities to intervene in strategies to improve the replicability, sustainability, and durability of HIV prevention interventions for drug users. *NIDA/CAMCODA Working Meeting*, Chevy Chase, MD, May 6-7, 2002. National Institute on Drug Abuse, U.S. Dept. of Health and Human Services, National Institutes of Health (Meeting Proceedings) July, 2003.

MULTICENTER TRIAL PUBLICATIONS

1. Harro CD, Judson FN, Gorse GJ, Mayer KH, Kostman JR, Brown ST, Koblin B, Marmor M, Bartholow BD, Popovic V, for the VAX004 Study Group. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. *J Acquir Immune Defic Syndr* 37(3):1385-92, 2004. (*Michelle A. Lally, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site*).
2. Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L, for the HIV Vaccine Trials Network. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. *J Infect Dis* 190(11):1962-9, 2004. (*Michelle A. Lally, Principal Investigator for HVTN 063 and HVTN 039, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN*).
3. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, Montefiori DC, Allen M, Chiu YL, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Keefer MC, Baden LR, Corey L, and the NIAID HIV Vaccine Trials Network. High-dose recombinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. *J Infect Dis* 192(7):1249-59, 2005. (*Michelle A. Lally, Principal Investigator for HVTN 039, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN*).
4. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, Creticos C, Orozco-Cronin P, Popovic V, and Mastro TD for the VISION/VAX004 Study Team. HIV sexual risk behavior over 36 months of follow-up in the world's first HIV vaccine efficacy trial. *J Acquir Immune Defic Syndr* 39(1):90-101, 2005. (*Michelle A. Lally, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site*).
5. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, Koblin B, Gurwith M, Bartholow B. Motivations for participating in an HIV vaccine efficacy trial. *J Acquir Immune Defic Syndr* 39(3):359-64, 2005. (*Michelle A. Lally, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site*).
6. Djomand G, Katzman J, Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS and the HIV Vaccine Trials Network. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. *Public Health Rep* 120(5):543-8, 2005. (*Michelle A. Lally, Principal Investigator for all*

- HVTN Studies Enrolled at Brown/Miriam HIV Vaccine Clinical Trial Site, 2001-2002*). PMC1497755
7. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, Deers M, Voss G, Koutsoukos M, Pedneault L, Vandepaperliere P, McElrath MJ, Spearman P, Fuchs JD, Koblin BA, Blattner WA, Frey S, Baden LR, Harro C, Evans T, and the **NIAID HIV Vaccine Trials Network (HVTN 041)**. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. *Vaccine* 25(3):510-8, 2006. (**Michelle A. Lally**, Principal Investigator for HVTN 041, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN).
 8. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, Weinhold KJ, Montefiori DC, Ferrari G, Horton H, Tomaras GD, Gurunathan S, Baglyos L, Frey SE, Mulligan MJ, Harro CD, Buchbinder SP, Baden LR, Blattner WA, Koblin BA, Corey L, and the **National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network**. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. *J Acquir Immune Defic Syndr* 44(2):203-12, 2007. (**Michelle A. Lally**, Principal Investigator for HVTN 203, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN). PMC2362395
 9. Fuchs J, Durham M, McLellan-Lemal E, Vittinghoff E, Colfax G, Gurwith M, Buchbinder S. Negative social impacts among volunteers in an HIV vaccine efficacy trial. *J Acquir Immune Defic Syndr* 46(3):362-68, 2007. (**Michelle A. Lally**, Principal Investigator for VAX004, Brown/Miriam HIV Vaccine Clinical Trial Site).
 10. Jaspan HB, Cunningham CK, Tucker TJP, Wright PF, Self SG, Sheets RL, Rogers AS, Bekker LG, Wilson CM, Duerr A, Wasserheit JN, and the **HIV Vaccine Adolescent Trials Working Group**. Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads. *J Acquir Immune Defic Syndr* 47(1):86-92, 2008. (**Michelle A. Lally**, Member of HIV Vaccine Adolescent Trials Working Group).
 11. Gorse GJ, Baden LR, Wecker M, Newman MJ, Ferrari G, Weinhold KJ, Livingston BD, Villafana TL, Li H, Noonan E, Russell ND, and the **HIV Vaccine Trials Network**. Safety and immunogenicity of cytotoxic T-lymphocyte polyepitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. *Vaccine* 26(2):215-23, 2008. (**Michelle A. Lally**, Principal Investigator for HVTN 048, Brown/Miriam HIV Vaccine Clinical Trial Site, HVTN).
 12. Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR, NIAID **HIV Vaccine Trials Network** (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force. Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients. *JAMA* 304(3):275-83, 2010. (**Michelle A. Lally**, Principal Investigator for the Phase I and II trials: HVTN 041, HVTN 042, HVTN 049, and HVTN 203 at the Brown/Miriam HIV Vaccine Clinical Trial site.)
 13. Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quick EK, Mehrotra DV. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. *J Infect Dis* 201(1):132-41, 2010. (**Michelle A. Lally**, Principal Investigator for Merck 007 and HVTN 050/Merck 018 at Brown/Miriam HIV Vaccine Clinical Trial site).

14. Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, MacElrath MJ, Lu S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. *PLoS One* 5(11):e13916, 2010. (**Michelle A. Lally**, Principal Investigator for HVTN 203 at Brown/Miriam HIV Vaccine Clinical Trial site.)
15. Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ. Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an AD5/HIV-1 vaccine candidate in humans. *PLoS One* 6(4):e18526, 2011. (**Michelle A. Lally**, Principal Investigator for HVTN050/Merck 018 at Brown/Miriam HIV Vaccine Clinical Trial site.)

PUBLICATIONS PENDING

ABSTRACTS

1. **Lally MA**, Feller AA, DiSpigno M, Pugatch D, Stein M, Mayer K. Testing for STDs at a detoxification center (abstract 612) *Nat'l HIV Prev Conf*, Atlanta, GA, September 1, 1999.
2. Pugatch D, Levesque BG, Ramratnam M, Towe CW, Strong L, **Lally MA**, Sullivan CD, Rich JD. HIV risk behaviors and HIV testing among adolescent and young adult substance abusers in inpatient detoxification centers. (abstract 235) 127th Meeting of the *Am Pub Health Assoc Conf*, Chicago, IL, November 7-11, 1999.
3. Beckwith CG, **Lally MA**. Missed Opportunities for HIV Screening: Patients Diagnosed with HIV in Rhode Island Hospital Over a Two-Year Period. (abstract) *R.I. Chapt Am College Physicians-Am Soc Int Med (ACP-ASIM)*, Annual Spring Meeting, Providence, RI, May 2-3, 2002.
4. Hou JC, Charuvastra A, Towe CW, **Lally MA**, Bandy U, Donnelly EF, Spaulding A, Rich JD. Risk factors for syphilis among incarcerated females in RI. (abstract 35) *7th Ann Res Celebr*, Providence, RI, November 9-10, 1999.
5. Levesque BG, Strong L, **Lally MA**, Flanigan T, Pugatch D. HIV testing among high risk adolescents and young adults: feasibility and acceptability in substance abuse treatment settings. (abstract 36) *7th Ann Res Celebr*, Providence, RI, November 9-10, 1999.
6. Pugatch D, Levesque B, Greene S, Strong L, Flanigan T, **Lally MA**. HIV testing in the setting of inpatient acute substance abuse detoxification services: a patient survey. (abstract) *12th Ann Nat'l HIV/AIDS Update Conf, Am Found AIDS Res*, San Francisco, CA, March 14-17, 2000.
7. **Lally MA**, Christiansen M, Alvarez S, MacNevin R, DiSpigno M, Pugatch D. Toward successful HBV vaccination among substance users in drug treatment: feasibility, acceptability and the role of financial incentives. (poster presentation, abstract 384) *Brown Univ Pub Health Prog Res Day*, April 19, 2001.
8. **Lally MA**, MacNevin R, Alvarez S, DiSpigno M, Pugatch D, Stein M. Acceptability of comprehensive counseling and testing among patients in short-term drug treatment. (poster presentation, abstract 4A) *Brown Univ Pub Health Prog Res Day*, April 19, 2001.

9. Pugatch D, Combs C, **Lally MA**, Harwell J, Flanigan T, Brown L. HIV testing among young injection drug users. (abstract 751843) *2001 Pediatr Acad Society Meeting*, Baltimore, MD. April 28, 2001.
10. Pugatch DL, Combs CM, **Lally MA**, Harwell JI, Flanigan TP, Brown, LK. HIV Testing among young injection drug users in substance abuse treatment. (abstract 450) *2001 Nat'l HIV Prev Conf*, Atlanta, GA, August 2001.
11. **Lally MA**, Christiansen MM, Alvarez SB, MacNevin RJ, DiSpigno MG, Pugatch DL, Stein MD. Toward successful HBV vaccination among substance users in drug treatment: feasibility, acceptability and the role of financial incentives. (abstract 384) *2001 Nat'l HIV Prev Conf*, Atlanta, GA, August 2001.
12. **Lally MA**, MacNevin RJ, Alvarez SB, DiSpigno MG, Pugatch DL, Stein MD. Acceptability of comprehensive counseling and testing among patients in short-term drug treatment. (abstract 342) *2001 Nat'l HIV Prev Conf*, Atlanta, GA, August 2001.
13. Novak R, Graham P, Brown-Peterside P, Koblin B, **Lally MA**, Mayer K, VaxGen 0044 Study Team. Comparison of men and women participating in a phase III HIV vaccine efficacy trial of AIDSVAX B/B in the US. (poster presentation, abstract 240) *AIDS Vaccine 2001*, Philadelphia, PA, September 5-8, 2001.
14. **Lally MA**, Shah P, Frater S, DiSpigno M, Pugatch, D. HIV testing with same day results. (poster presentation, abstract 322) *2002 Nat'l STD Prev Conf*, San Diego, CA, March 4-7, 2002.
15. Pugatch D, O'Connell JV, Smith KA, Soares JJ, Brown LK, D'Angelo L, **Lally MA**. Hepatitis C prevalence in young adult drug users in Rhode Island. (abstract) *2003 Pediatr Academ Soc Meeting*, Seattle, WA, May 3-5, 2003.
16. DeGroot AS, Sbail H, Bishop EA, Foti S, Franco J, **Lally MA**, Weiner DB, Mayer KH, Carpenter CCJ, Martin W. Developing an immunogenic consensus sequence T cell epitopes for the GAIA cross-clade HIV vaccine. (abstract 1:55) *2003 HIV Vaccines: Design-Potency-Delivery*, Cambridge, MA, June 22-23, 2003.
17. **Lally MA**, Ryan H, Snyder B, Malia JA, Michael NL. The REVEAL™ rapid HIV test is sensitive and easy to perform (abstract T2-C1504). *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.
18. **Lally MA**, Frater SC, DiSpigno MG, Shah P, Delgadillo O, Pugatch D, Flanigan TP. HIV testing with next day results among women in drug treatment (oral presentation, abstract M1-G0501). *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.
19. **Lally MA**, Gaitanis MM, Khan B, DiSpigno M, McNevin RJ, Stein, MD. Hepatitis vaccination among substance users: A model for HIV vaccine delivery. (oral presentation, abstract M1-C0201) *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.
20. Pugatch D, **Lally MA**, O'Connell JV, Smith KA, Soares JJ, Brown LK, D'Angelo L, Flanigan TP, Stein M. Testing young substance abusers for HIV and hepatitis outside of a drug treatment center. (oral presentation, abstract TI-G0602) *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.
21. **Lally MA**, Montstream-Quas SA, Tanaka SM, Rosen RK, Morrow, KM. Increasing HIV and viral hepatitis testing for women. (oral presentation, abstract MP-097) *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.

22. **Lally MA**, Gaitanis MM, Vallabhaneni S, Ryan H, Zimet GD, Mayer K, Rich JD. Attitudes toward HIV vaccination among Rhode Island inmates (poster presentation, abstract TP-050). *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.
23. **Lally MA**, Montstream-Quas SA, Tanaka SM, Rosen RK, Morrow KM. Barriers and facilitators for infectious disease testing and results: what female injection drug users are saying about HIV and viral hepatitis. (poster presentation, abstract MP-097) *2003 Nat'l HIV Prev Conf*, Atlanta, GA, July 27-30, 2003.
24. Gaitanis MM, Alvarez S, Mayer K, **Lally MA**. Selective case management use among high-risk women in two studies: a retrospective analysis. (abstract 498) *AIDS Vaccine Conf*, New York, NY, September 18-22, 2003.
25. Bishop E, Martin W, **Lally MA**, Mayer K, DeGroot A. Immunogenic consensuses sequences MHC class II epitopes for the GAIA cross-clade HIV vaccine. (poster presentation, abstract 366) *2003 HIV Vaccine Conf*, New York, NY, September 18-22, 2003.
26. Spearman P, **Lally MA**, Chiu J, Russell N, Rossini A, Vardas E, Dorenbaum A, Izu A, Barnett S, Donnelly J, Duliege A-M. Human trials of gag and env DNA/PLG microparticle priming followed by Oligomeric gp140 boosting: A collaborative effort between NIAID, HVTN, and Chiron Corporation. (poster presentation, abstract 385) *2003 HIV Vaccine Conf*, New York, NY, September 18-22, 2003.
27. Soares J, Blanton E, Losikoff P, Smith K, Gaitanis M, O'Connell J, Flanigan T, **Lally MA**, Pugatch D. The need for hepatitis B vaccination and hepatitis C prevention among 18-25 year old substance users in Rhode Island. (abstract) *Infect Dis Soc America*, San Diego, CA, October 11, 2003.
28. Pugatch D, O'Connell JV, Glanton E, Smith KA, Elson LC, Mayer K, Flanigan TP, Brown LK, **Lally MA**. Developing an HIV rapid testing initiative for youth. (poster presentation, abstract TuPeC4895) *XV Int'l AIDS Conf*, Bangkok, Thailand, July 11-16, 2004.
29. Marcon L, Martin W, Franco JI, Bishop EA, Rivera D, **Lally MA**, Kutzler M, Weiner DB, Mayer KH, DeGroot AS. Elicitation of De Novo T-cell responses in mice immunized with a multi HIV-1 epitope cross-clade DNA vaccine. (oral presentation) *AIDS Vaccine 2004*, Lausanne, Switzerland, August 30-September 1, 2004.
30. Harro C, Edupuganti S, Goepfert P, Priddy F, **Lally MA**, Shiver J, Li X, Robertson M, Leavitt R, Isaacs R, and the V520-007 and V520-012 Study Groups. Safety and immunogenicity of adenovirus type 5 (Ad5) HIV-1 gag vaccines. (oral presentation, abstract G-115) *12th Conf Retrovir Opportun Infect*, Boston, MA, February 22-25, 2005.
31. Goepfert P, Priddy FH, Spearman PW, Harro C, Edupuganti S, **Lally MA**, Gurunathan S, Bagliyos L, Shiver JW, Mehrotra D, Due L. Boosting adenovirus serotype 5 (Ad5) HIV-gag primed subjects with ALVAC HIV (vCP205) (poster presentation, abstract G-116) *12th Conf Retrovir Opportun Infect*, Boston, MA, February 22-25, 2005.
32. Manalo R, Tedeschi SK, **Lally MA**, Gaitanis MM, Mayer K, Shepardson S, Rich JD. Vaccination in juvenile correctional facilities: state laws, hepatitis B, and the impact on anticipated sexually transmitted infection vaccines. (oral presentation, abstract MR-046) *2005 Nat'l HIV Prev Conf*, Atlanta, GA, June 12-15, 2005.
33. Dubowitz N, **Lally MA**, Feller E, Mitty J. The creation of a visual card: illustrating the importance of adherence to HAART (poster presentation, abstract TP-062) *2005 Nat'l HIV Prev Conf*, Atlanta, GA, June 12-15, 2005.

34. Beckwith CG, Atunah-Jay S, Cohen J, **Lally MA**, Poshkus M, Rich JD, Flanigan TP. Feasibility and acceptability of rapid HIV testing in jail (oral presentation, abstract M2-F0702) *2005 Nat'l HIV Prev Conf*, Atlanta, GA, June 12-15, 2005.
35. **Lally MA**, Tedeschi S., Parekh M, Gaitanis M, Pugatch D, Zimet G, Mayer K. Adolescent attitudes toward HIV vaccine trials: barriers for young women's participation. (oral presentation, abstract 80) *AIDS Vaccine 2005 Conf*, Montreal, Quebec, Canada, September 6-9, 2005.
36. Beckerman J, Vu N, Keita N, Koné, DeGroot A, **Lally MA**, Mayer K. Potential barriers to an HIV vaccine trial in Bamako Mali. (poster presentation, abstract 320) *AIDS Vaccine 2005 Conf*, Montreal, Quebec, Canada, September 6-9, 2005.
37. Rivera D, Boren C, Bishop E, Martin W, **Lally MA**, Mayer K, DeGroot A. Mapping and confirming highly conserved HLA B7-restricted epitopes for the GAIA vaccine. (poster presentation, abstract 432) *AIDS Vaccine 2005 Conf*, Montreal, Quebec, Canada, September 6-9, 2005.
38. Bishop E, Marcon L, Martin W, Koita O, **Lally MA**, Mayer K, DeGroot A. Cross-presentation of confirmed A3 supertype T cell epitopes selected for the GAIA cross-clade HIV vaccine. (poster presentation, abstract 434) *AIDS Vaccine 2005 Conf*, Montreal, Quebec, Canada, September 6-9, 2005.
39. Marcon L, Martin B, Bishop E, Rivera D, **Lally MA**, Kutzler M, Weiner D, DeGroot A. Expanded T cell response repertoire achieved by a HLA A2 multi-epitope cross-clade HIV vaccine in the presence of IL-15. (poster presentation, abstract 712) *AIDS Vaccine 2005 Conf*, Montreal, Quebec, Canada, September 6-9, 2005.
40. DeGroot A, Koné M, Mayer K, **Lally MA**, Marcon L, Koita O, Kutzler M, Weiner D. GAIA HIV vaccine development: optimization of the immunogens in pre clinical studies. (poster presentation, abstract 913) *AIDS Vaccine 2005 Conf*, Montreal, Quebec, Canada, September 6-9, 2005.
41. Tedeschi SK, **Lally MA**, Parekh MJ, Gaitanis MM, Mayer KH, Zimet GD. Attitudes of at-risk adolescents and their parents toward anticipated HPV and HIV vaccines (poster presentation, abstract 39). *Society Adolesc Med*, 2006 Annual Meeting, March 22-25, 2006.
42. Cohen C, Kone M, LaFaunce A, Vu N, **Lally MA**, Mayer KH, Keita N, DeGroot AS. Knowledge, attitudes, and practices study in marketplaces of Bamako, Mali to inform the design of HIV vaccine trials (Abstract 231.00) *AIDS Vaccine 2006 Conf*, Amsterdam, The Netherlands, August 2, 2006.
43. DeGroot, AS, Goldberg M, Rivera D, McMurry JA, Moise L, Kone M, Koita OA, Marcon L, Kutzler M, **Lally MA**, Mayer KH, Weiner DB, Martin WD. 2006 progress update on the GAIA HIV vaccine: broad coverage by HLA alleles and geographic location, Optimization of HIV immunogens in pre clinical studies (Abstract 438.00) *AIDS Vaccine 2006 Conf*, Amsterdam, The Netherlands, August 2, 2006.
44. Marcon L, Moise L, Rivera D, **Lally MA**, Kutzler M, McMurry JA, Martin WD, Weiner DB, DeGroot AS. Elicitation of robust T cell responses in HLA DRB1*0101 transgenic mice by MHC class II compartment-targeted and untargeted HIV T helper multiepitope molecular constructs (Abstract 441.00) *AIDS Vaccine 2006 Conf*, Amsterdam, The Netherlands, August 2, 2006.
45. Kibler JL, Ma M, Bartholow BN, Durham MD, Sarpong D, **Lally MA**, Mayer KH. Correlates of willingness to participate in microbicide research among African-American

- adults in Mississippi. (oral presentation) *Annual Society of Behavioral Medicine*, Washington, DC, March, 2007.
46. Bonney LE, Assoumou S, Wang CC, Stein M, Flanigan T, **Lally MA**. Pediatricians intend to implement reminder/recall systems to enhance human papilloma virus vaccination among adolescents. (poster presentation, #94) *Future of Pediatrics: Community Pediatrics, The Medical Home, and Beyond*, Orlando, FL, June 29-July 1, 2007.
 47. **Lally MA**, Mitty J, Morrow KM, Wang CC. Is a misleading term driving adherence among persons with well-controlled HIV infection? (Abstract A-042-0107-05178) *4th International AIDS Society Conf*, Sydney, Australia, July 22-25, 2007.
 48. **Lally MA**, Bonney LE, Wang CC. Completing the HPV vaccine series: a tool that may be helpful? (abstract A-042-0156-01339) *4th International AIDS Society Conf*, Sydney, Australia, July 22-25, 2007.
 49. Bonney LE, Gillani F, Zimet G, **Lally MA**. HPV and HPV vaccine attitudes differ by race and ethnicity in a sample of young women. (poster presentation, #862). *Infectious Diseases Society of America, 45th Annual Meeting*, San Diego, CA, October 4-7, 2007.
 50. **Lally MA**, O'Connell R, Peel S, Michael N, Jagodzinski L. Nucleic acid detection in patients whose HIV RNA levels are near the lower limit of detection: implications for endpoint determination in HIV vaccine trials (poster presentation, abstract G-107) *15th Conf Retrovir Opportun Infect*, Boston, MA, February 4-6, 2008.
 51. **Lally MA**, Goldsworthy R, Sniecinski K, Zimet G. Development of Tools to Reduce Preventive Misconception Among Adolescents in HIV Vaccine Trials (poster presentation) *AIDS Vaccine 2010*, Atlanta, Georgia September 28-October 1, 2010.
 52. Nugent NR, **Lally MA**, Knopik V, Brown L, McGeary J. OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV (paper presentation) *Behavior Genetics Association*, Newport, RI, June 6-9, 2011.
 53. Nugent NR, **Lally MA**, Brown L, Knopik V, Frater, S, McGeary J. Serotonin transporter gene and distress intolerance in binge drinkers living with HIV (poster presentation) *Behavior Genetics Association*, Newport, RI, June 6-9, 2011.
 54. Larson E, **Lally MA**. Secondary Prevention Counseling among HIV-Infected Persons with Detectable Viral Loads. 2011 National HIV Prevention Conference, Atlanta, GA, August 14-17, 2011.
 55. Jagodzinski L, Liu Y, Weston H, Frater S, O'Connell R, Peel S, Nelson M, **Lally M**. Nucleic Acid Detection of HIV-1 in HIV Infected Individuals Having Well Controlled Viremia. *19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)*, Seattle, WA, March 5-8, 2012.
 56. Ming L, **Lally M**, Ramratnam B. Proteomics of HIV-1 Control. *19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)*, Seattle, WA, March 5-8, 2012.
 57. Alexander NE, Flanigan T, Chan P, Chowdhury S, **Lally M**, Beckwith C. Seek, test, treat, retain state-wide strategy: mobilizing leadership in Rhode Island (oral poster presentation). *2012 International HIV Treatment as Prevention (TasP) Workshop*, Vancouver, BC, April 22-25, 2012.
 58. Hosek S, Siberry G, **Lally M**, Bell, M, Fernandez I, Rutledge B, Rooney J, Kapogiannis B, Wilson C, and the Adolescent Trials Network (ATN) for HIV/AIDS Interventions. A First Look at Open Label Pre-Exposure Prophylaxis Use among Young Men Who Have

Sex with Men. 4th *International Workshop on HIV Pediatrics*, Washington, DC, July 20-21, 2012.

59. Larson HE, **Lally M**, Wiley C, Worthen D. Oral Pre-exposure Prophylaxis to Prevent HIV-1 Infection in High-risk Adults: Implications for Clinical Pharmacy Practice. (oral presentation) *1st International Conference on Frontiers in Pharmaceutical Sciences: Global Perspectives*, Kingston, RI. September 28-30, 2012.

INVITED PRESENTATIONS

1. Invited Speaker, "HIV Medical Update/HIV Vaccine Studies." Charlton Memorial Hospital, Fall River, MA, November 5, 1999.
2. Invited Speaker, "Comprehensive Counseling and Testing among Patients in Short-term Drug Treatment." Massachusetts Department of Health, Jamaica Plains, MA, June 27, 2001.
3. Infectious Diseases Lecture Series, "An Update on HIV Vaccine Trials: Will an Adenoviral Vector Work Best?" The Miriam Hospital, Providence, RI, April 21, 2004.
4. Invited Panelist, "Preventing HIV and AIDS in the Future," Brown University Pandemic AIDS Symposium." Brown University, Providence, RI, April 23-25, 2004.
5. *Invited Speaker, "Communicating Scientific Concepts Clearly and in Simple Terms," Strategic Communications Workshop, HVTN Full Group Meeting, Washington, DC, May 3-5, 2004.*
6. Invited Speaker, "HIV Vaccine Research Efforts: In Rhode Island and Around the World" HIV Vaccine Awareness Day Symposium, Brown University, Providence, RI, May 13, 2004.
7. Invited Speaker, "Linking HIV Treatment and Prevention Services in the Community," Family Resources Community Action, Woonsocket, RI, June 17, 2004.
8. Invited Speaker, "Women and Girls: Past, Present, and Looking to the Future," World AIDS Day, 2004, The MET School Blackbox Theater, Providence, RI, December 4, 2004.
9. Invited Speaker, "An HIV Vaccine is our Best Hope of Preventing AIDS" World AIDS Day Event, Providence, Rhode Island, December 4, 2004.
10. Invited Speaker, "AIDS Vaccine," 57th Clinical Laboratory Science Society of Central New England, Annual Meeting, RI Convention Center, Providence, RI, May 11, 2005.
11. Invited Speaker, "HIV Vaccine Trials in Rhode Island: How Rhode Island is Making a Difference". HIV Vaccine Awareness Day Symposium, Providence, RI, May 18, 2005.
12. Invited Speaker, "Why an HIV Vaccine Matters to Minority Women in Rhode Island" World AIDS Day Event, December 2, 2005.
13. Invited Panelist, "National Black HIV/AIDS Awareness Day Event," Sponsored by The Miriam Hospital's HIV Prevention Programs, Columbus Theatre, Providence, RI, February 7, 2006.
14. Invited Speaker: "HIV Among African Americans: A Preventable Disease, A Treatable Disease," National Association for the Advancement of Colored People (NAACP), Providence Health Fair, Rhode Island College, March 25, 2006.

15. Invited Speaker, "Delivering the HPV Vaccine to At-Risk Youth," Clinical AIDS Task Force, The Miriam Hospital, Providence, RI, May 3, 2006.
16. *Invited Faculty Member, Workshop: "HVTN Scientists' Breaking Down the Science for Community Educators," Washington, DC, May 22, 2006.*
17. Invited Speaker, "HPV Vaccine Delivery," The 2nd Vaccine Renaissance, RI, Conference, Westin Hotel, Providence, RI, June 9, 2006.
18. Invited Speaker, "HPV Vaccine Update," HIV/HPV Among Women, Brown University AIDS Program, Providence Marriot Hotel, Providence, RI, June 21, 2006.
19. Conference Organizer and Speaker, "Evening Viral Lecture Series," The Miriam Hospital, Department of Infectious Diseases, The HI-Hat, Providence, RI, October 26, 2006.
20. *Invited Speaker, "HPV and HIV Disease Incidence and Interactions Worldwide," HPV and HIV: A Discussion on Potential Research Questions, Walter Reed Army Institute Research, Rockville, MD, March 15, 2007.*
21. *Invited Speaker, "VRC Adolescent Concept: Multiclade and Multinetwork," HVTN Full Group Meeting, Washington D.C., May 1-3 2007.*
22. Invited Participant: "In Her Mother's Shoes" Symposium, The Global Threat of HIV Among Women: Challenges and Responses, Panel VIII: The Search for an Effective Preventive HIV Vaccine, The Warren Alpert Medical School of Brown University, Providence, RI, May 5-6, 2007.
23. Invited Participant, "Novel Technologies in Rapid HIV NAT Assay Diseases," Rapid HIV-1 Viral Detection Workshop, Bethesda, MD, July 12-13, 2007.
24. Invited Speaker: "HIV Vaccine Induced Seropositivity: Can Nucleic Acid Testing Diagnose Infection?" Department of Medicine, Infectious Disease Conference, The Miriam Hospital, September 12, 2007.
25. Invited Speaker, "An Update on New Adult Immunizations: Tdap, Zoster, and HPV," 2007 Internal Medicine Update, American College of Physicians, The Rhode Island Chapter, and the Warren Alpert Medical School of Brown University, Hyatt Regency Hotel, Newport, RI, October 10, 2007.
26. Invited Speaker, "HPV Disease Update," Annual Vaccine Update for Rhode Island High School Nurse Educators, Rhode Island Department of Health, "Vaccinate Before You Graduate" Program, The Wellness Company, Providence, RI, October 9, 2007.
27. *Invited Speaker, "Early Stopping of Phase IIB Proof of Concept Trial of Merck AD5 Vaccine," IMPAACT Vaccine/Immunobased Therapy Scientific Committee Meeting, Hyatt Hotel, Washington, DC, October 10-12, 2007.*
28. *Invited Speaker, "Early Stopping of the STEP Trial," ATN Network Meeting, Hilton Hotel, Silver Spring, MD, October 16-19, 2007.*
29. Invited Speaker, "Adult Immunization Update," Medical Grand Rounds, Rhode Island Hospital, Providence, RI, April 29, 2008.
30. Invited Speaker, "Immunization Update," Resident Lecture Series, The Miriam and Rhode Island Hospitals, Providence, RI, August 26, 2008.
31. Invited Speaker, "HPV Vaccine Update," Infectious Diseases Conference, The Miriam Hospital, Providence, RI, August 28, 2008.

32. Invited Speaker, "Immunization Update," Resident Lecture Series, Rhode Island Hospital, Providence, RI, September 25, 2008.
33. Infectious Diseases Fellows Lecture Series, "HIV Vaccines Update," The Miriam Hospital, Providence, RI, March 17, 2010.
34. Invited Speaker, "HIV Prevention Among Vulnerable Youth," New England Medical Center, October 13, 2010
35. Clinical AIDS Task Force Lecture Series, "Pre-Exposure Prophylaxis Against HIV Infection: A Discussion of iPREX Study Results and the Implications for PrEP Rollout," The Miriam Hospital, Providence, RI, December 1, 2010.
36. Internal Medicine Noon Conference, "Immunizations," Rhode Island Hospital, Providence, RI, December 3, 2010.
37. Internal Medicine Noon Conference, "Immunizations," Rhode Island Hospital, Providence, RI, December 7, 2010.
38. Invited Keynote Speaker, "Barriers to Adult Immunization," Ocean State Adult Immunization Coalition Winter Meeting, Warwick Public Library, Warwick, RI, February 16, 2011.
39. Invited Speaker, "An Update on Vaccine Science and Policy," Infectious Diseases Conference, The Miriam Hospital, Providence, RI, March 10, 2011.
40. Invited Presenter: "ATN Plenary Session," Adolescent Trials Network Meeting (ATN), Doubletree Bethesda Hotel, Bethesda, MD, April 10-13, 2011.
41. Paper Presentation: "OPRM1 and Diagnosis-Related Posttraumatic Stress disorder in Binge-Drinking Patients Living with HIV," 2011 Behavior Genetics Association's 41st Annual Meeting Conference, Hotel Viking, Newport, RI, June 6-9, 2011.
42. Poster Presentation: "Serotonin Transporter Gene and Distress Intolerance in Binge Drinkers Living with HIV," 2011 Behavior Genetics Association's 41st Annual Meeting Conference, Hotel Viking, Newport, RI, June 6-9, 2011.
43. Invited Participant, Roundtable Session: "Women, Vulnerable Populations and AIDS," 2011 Brown International Advanced Research Institutes (BIARI) Global Health Institute on HIV/AIDS, Brown University, Providence, RI, June 22, 2011.
44. Invited Speaker, "Immunizations Needed in Underserved Communities," Lifespan Health Advocates, Lifespan, Providence, RI, September 27, 2011.
45. Moderator, "Secondary Prevention in the Immunology Clinic," Lifespan/Tufts/Brown CFAR Research-in-Progress Lecture Series, Providence, RI, September 30, 2011.
46. Invited Speaker: "Biomedical Intervention in the Prevention of HIV/AIDS: PrEP, PEP, PMTCT, Circumcision, Microbicides, 'Test to Treat,'" Rhode Island Association of Nurses in AIDS Care, Radisson Airport Hotel, Warwick, RI, October 28, 2011.
47. Invited Speaker, Fellows Immunization Lecture, New England Medical Center, Boston, MA, November
48. Invited Lecturer, "Enrolling Adolescents in HIV Prevention Trials to Examine Biomedical Interventions," Indiana University Leadership Education in Adolescent Health seminar series, Indianapolis, IN, January 24, 2012.
49. Presenter, "CROI 2012 Update," Clinical AIDS Task Force, Brown University AIDS Program, Providence, RI March 14, 2012.
50. Workshop Presenter, "Connect to Protect (CP)®: Using Community Mobilization to Create Structural Change. The 15th Annual MAI Summit on HIV and Adolescents, New England AIDS Education and Training Center, Taunton, MA, March 23, 2012.

51. Invited Speaker, "HIV Prevention Research and Trials among Adolescents in US," 2012
Brown International Advanced Research Institutes (BIARI) Global Health Institute on
HIV/AIDS, Brown University, Providence, RI, June 12, 2012.

GRANTS

Award amounts include both direct and indirect costs unless otherwise indicated.

CURRENT GRANTS

1. HIV Vaccine Trials Network Liaison for Adolescent Trials
HIV Vaccine Trials Network at Fred Hutchinson Cancer Research Center/ NIH -
5U01AI068614

6/1/06-5/31/13: \$10,500/year: \$365,363/ anticipated total award (year by year subcontract)
Principal Investigator: Michelle A. Lally, MD, MSc

HVTN leadership position to serve as lead HVTN investigator for adolescent issues, and as liaison to other NIH-sponsored networks, the Adolescent Medicine Trials Network (ATN) the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), in an effort to facilitate the development of adolescent HIV vaccine trials.

2. Adolescent Trials Network: Adolescent Medicine Leadership Group/ NIH-
1U01HD040533

03/01/08-02/29/16: \$70,000/year: \$93,342/ anticipated total award (year by year subcontract)
Principal Investigator: Michelle Lally, MD, MSc

Asked to support the Adolescent Medicine Leadership Group and to serve as the Chair of the Community Prevention Leadership Group of the NIH-funded ATN in the formulation of hypotheses and review of proposals submitted to the Network for scientific merit and feasibility. The primary mission of the ATN is to explore promising behavioral, microbicidal, prophylactic, therapeutic, and vaccine modalities in HIV-infected and HIV at-risk adolescents, age 12 through 24.

3. A Phase III Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine: Merck 503-006

2/02/10-Indefinite: 49,500/ total award (directs)
Principal Investigator: Michelle Lally, MD, MSc

This Phase III study is evaluating the efficacy of a Multivalent PHV vaccine.

4. New England AIDS Education and Training Center
7/01/11-6/30/13: \$101,600/year
Principal Investigator: Michelle Lally, MD, MSc

This project supports the training and education of HIV care providers throughout New England. Dr. Lally is the PI of the Rhode Island local performance site for this project and oversees Rhode Island based trainees as well as Rhode Island LED trainings throughout New England.

5. Center for AIDS Research – Prevention Core, Director, NIH/NIAD 3P30AI042853

9/1/98 – 6/30/2017; \$132,000

The broad goals of this program are 1) to stimulate translational AIDS research with women, minorities, and other under-represented groups; 2) to enhance research in prevention science; 3) to integrate nutritional assessment/intervention and outcomes analysis into clinical research; 4) to encourage multidisciplinary research on the clinical issues surrounding new therapies and the accompanying extended survival of HIV(+) patients; and 5) to explore effective screening, treatment and prevention of viral-induced carcinomas in AIDS patients.

6. Adolescent Trials Unit, NIH/NICHD, 1U001HD068040

6/1/2011 – 2/29/2016; \$10,693

The Fenway ATU is a multidisciplinary collaboration of HIV prevention and treatment researchers and community health providers serving at-risk and HIV- infected adolescents in greater Boston.

COMPLETED GRANTS

1. VAX 004: A Phase III Trial to Determine the Efficacy of Bivalent AidsVax™ B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America and Europe (VAX004)

09/01/99 – 03/30/02: \$132,397/ total award

Principal Investigator: Michelle A. Lally, MD, MSc

2. Project Prevent (Ittleson Foundation)

06/01/00 – 06/01/02: \$40,000/ total award

Principal Investigator: Michelle A. Lally, MD, MSc

3. Hepatitis C Testing among People in Drug Treatment
Massachusetts Department of Public Health

06/01/00 – 06/30/02: \$144,500/ total award

Principal Investigator: SSTAR/Michelle A. Lally, MD, MSc

4. HIV/Infectious Disease Testing/Treatment in Substance Abusers
National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA) –
1K23DA00460-01A1

10/01/00 – 01/30/06: \$134,224/year: \$686,429/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

5. HIV Rapid Testing among Substance Abusers
National Institutes of Health, National Institute on Drug Abuse (NIH/NIDA) –
RO3 1RO3MH62683-01

10/01/00 – 08/31/03: \$69,583/year: \$140,583/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

6. Validation of Candidate HIV Vaccine T Cell Epitopes
National Institutes of Health/Brown University TB/HIV Program
Principal Investigator: Anne DeGroot, MD: 7RO1AI050528

05/01/02 - 04/30/06: \$29,928/year/ \$119,753/ total award
Principal Investigator at Miriam Hospital for Subcontract: Michelle A. Lally, MD, MSc

7. Vaccination Against HIV and HPV: Attitudes and Acceptability
Among Young Women and Their Parents
Center for AIDS Research Developmental Grant Program

06/01/04 - 05/31/06: \$30,000/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

8. MAP's Targeted HIV Outreach Program: Project Faith and Sara's Light
Centers for Disease Control and Prevention/MAP Alcohol
and Drug Rehabilitation Services, Inc.

06/01/04 - 05/31/06: \$10,000/year/ \$ 20,000/ total award
Principal Investigator at Miriam Hospital: Michelle A. Lally, MD, MSc

9. HIV Vaccine Trials Network (HVTN)
NIH award to Harvard Medical School - 1 UO 1AI48023-01
Subcontract from Harvard Medical School for the Providence HIV Vaccine Clinical Trial Unit
(HVTU) from 06/01/01 - 12/30/08:

\$412,000/year : \$ 2,900,000 /total award (to Lifespan)
Principal Investigator for Providence HVTU: Michelle A. Lally, MD, MSc

10. A Probe Study of the Safety, Tolerability and Immunogenicity of a 3-Dose Regimen of Ad5
Human Immunogenicity Virus (HIV-1) gag Vaccine in Healthy Adults (Merck 007)

03/30/01 – 12/31/08: \$164,782/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

11. Merck 027: A Phase IIA Dose-Refinement Study of the Merck Adenovirus
Serotype HIV-1 gag/pol/nef (MRKAd5 HIV-1 Trivalent Vaccine) in Healthy Adults (Merck
027)

10/1/06-09/30/08: \$125,562/ total award
Principal Investigator: Michelle Lally, MD, MSc

12. Adolescent Vaccination against HPV
The Boston Celtics Foundation
10/01/06-09/30/09: \$50,000/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

13. A Phase I Dose-Ranging Study of the Safety, Tolerability, and Immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV1 gag/pol/nef Vaccine (MRKAd5 HIV-1 gag/pol/nef) in a Prime-Boost Regimen in Healthy Adults (Merck 016-Trivalent)
06/01/03 - 05/31/09: \$159,856/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

14. Merck 022 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection
06/01/04- 10/01/10: \$84,158/total award
Principal Investigator: Michelle A. Lally, MD, MSc

15. A Probe Study of the Safety, Tolerability and Immunogenicity of a 1-Dose Regime of the MRKAd5 HIV-1 Gag Vaccine versus the ALVAC-HIV (vCP205) Vaccine in Healthy Adults Who Previously Received a 3-Dose Regimen of MRKAd5, Ad5 or Placebo in Merck V520 Protocols 007 or 012 (Merck 019)
10/30/03 - 09/01/10: \$95,030/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

16. Merck 001 A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3 Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and In Combination in Healthy Adults
4/1/05- 01/31/11: \$98,110/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

17. Nucleic Acid Assays for Diagnosis of HIV in Anticipation of an HIV Vaccine Henry M. Jackson Foundation for the Advancement of Military Medicine –W81XWH-04-2-005
10/01/06-03/31/11 : \$256,615/year :\$641,538/ total award
Principal Investigator: Michelle A. Lally, MD, MSc

HIV vaccine recipients can develop HIV antibodies that lead to false positive HIV test results using traditional serology. This study is evaluating the sensitivity and specificity of nucleic acid assays for detecting true HIV infection among a population with well controlled HIV disease that simulate recipients of an HIV vaccine. The US Military is actively evaluating HIV vaccine candidates and are collaborators on this project.

18. A Study of a Multivalent Human Papillomavirus (HPV) Vaccine Compared with GARDASIL® in 16- to 26-Year-Old Women HIV Vaccine Study (Merck 503-001)

09/01/07-08/31/11: \$134,637/ total award
Principal Investigator: Michelle Lally, MD, MSc

19. Project to Explore the Proteomics of HIV/ NIH (ARRA)
3P30AI042853-13S1 (CFAR Supplement)
8/30/10-6/30/12: \$114,348/ total award (directs)
Principal Investigator: Michelle Lally, MD, MSc

This project aims to explore the proteomic variability among persons with HIV who control their disease as compared to non controllers, and also among persons with HIV exposure.

20. RV284: Cohort Development to Determine Genetic Mechanisms of Protection from HIV-1 Acquisition Among Persons at Risk for HIV infection/ Henry Jackson Foundation- W8IXWH-07-2-0067
8/1/09-9/30/12: \$1,666,778/total award
Principal Investigator: Michelle Lally, MD, MSc

This project aims to develop a cohort of persons at risk for HIV infection through HIV exposure in order to determine genetic markers of protection from HIV infection.

UNIVERSITY TEACHING ROLES

2000	Small Group Sessions Facilitator BioMed 282 – Pathophysiology, Infectious Diseases Received The Dean’s Teaching Excellence Award “In Recognition of Exemplary Teaching”
2007	Small Group Sessions Facilitator Bio 365 – Pathophysiology, Infectious Diseases Received The Dean’s Teaching Excellence Award “In Recognition of Exemplary Teaching”

HOSPITAL TEACHING ROLES

1998 -	Infectious Disease Attending The Miriam Hospital, Providence, RI (Approximately two months per year)
1998 -	Immunology Center/HIV Clinic Inpatient Service The Miriam Hospital, Providence, RI (Approximately one month per year)
1998 - 2002	Immunology Center/HIV Clinic Attending The Miriam Hospital, Providence, RI (Approximately one clinical session per week)
2006 - 2010	Miriam Hospital Travel Clinic Attending (Approximately one clinical sessions per week)

OTHER TEACHING ROLES

1998 - 2000	HIV Medical Clinic for Incarcerated Women Adult Correctional Institute, Cranston, RI (Approximately one clinic session per week)
1998 - 2001	Stanley Street Treatment and Resources (SSTAR) Short Term Drug Treatment Center, Providence, RI (Approximately one clinical session per week)
2005 -	Fellows Lecture Series Rhode Island Hospital
2005 -	Resident Lecture Series The Miriam Hospital

HOSPITAL/UNIVERSITY TEACHING ROLES (TRAINEES)

June, 1999 - August, 1999	Mentor, Summer Research Assistantship ➤ <u>Alex Feller</u> <i>Project:</i> “Comprehensive Testing for HIV and Other Sexually Transmitted Infections in the Drug Treatment Setting” <i>Progress:</i> Dr. Feller worked with me while he was an undergraduate at Brown. He has since graduated from Brown Medical School, completed a residency in psychiatry, and is a psychiatrist at Columbia University Medical Center in New York.
September, 1999 - May, 2000	Mentor, Brown University BioMed 195/196 Independent Study ➤ <u>Jess Kaplan</u> <i>Project:</i> Brown University Undergraduate “A Pilot Study of Comprehensive Testing for Infectious Diseases among Women in Drug Treatment.”
September, 1999 - May, 2000	Mentor, Brown University BioMed 195/196 Independent Study ➤ <u>Sara Tanaka</u> <i>Project:</i> “A Qualitative Study of Comprehensive Testing for Infectious Diseases among Women in Drug Treatment” <i>Progress:</i>

Sara Tanaka graduated from Brown University, completed medical school at the University of Chicago, and is currently an Internal Medicine Physician at the University of Chicago Hospitals.

September, 2000 - May, 2001 Mentor, Brown University Biology and Community Health BC 196, Independent Study

➤ Molly Christiansen

Project:

Brown Undergraduate

“A Pilot Study of Hepatitis B Testing and Vaccination Among Women in Drug Treatment”

Progress:

Molly Christiansen graduated from Brown University and then went on to earn an MPH and an MBA from the University of Michigan. She currently works as the Director for Research and Development at Living Goods. (Living Goods is building a sustainable distribution platform for products designed to fight poverty and disease in the developing world.)

June, 2000 - August, 2000 Advisor, Undergraduate Teaching and Research Assistantship (UTRA)

➤ Molly Christiansen

Project:

“Testing and Vaccinating Substance Abusing Women for Hepatitis B”

Progress:

Molly Christiansen graduated from Brown University and then went on to earn an MPH and an MBA from the University of Michigan. She currently works as the Director for Research and Development at Living Goods.

September, 2000 - May, 2001 Advisor, Senior Honor Thesis, Brown University

➤ Sara Tanaka

Project:

“Opportunities to Increase Medical Care for Female Injection Drug Users”

Progress:

Sara Tanaka graduated from Brown University, completed medical school at the University of Chicago, and is currently an Internal Medicine Physician at the University of Chicago Hospitals.

Progress:

Sara Tanaka graduated from Brown University, completed medical school at the University of Chicago, and is currently an Internal Medicine Physician at the University of Chicago Hospitals.

➤ Molly Christiansen

Project:

“A Qualitative Study of Comprehensive Testing for Infectious Diseases among Women in Drug Treatment”

Molly Christiansen graduated from Brown University and then went on to earn an MPH and an MBA from the University of Michigan. She currently works as the Director for Research and Development at Living Goods.

May, 2000 -
August, 2001

Mentor, Research Assistantship

➤ Ryan MacNevin

Project:

“Comprehensive Testing for HIV, Viral Hepatitis, and STIs at a Drug Treatment Center”

Progress:

Dr. MacNevin started medical school at the University of Maryland in August, 2001, graduated in May 2005, and returned to Brown for his Internal Medicine internship and residency (2005 - 2008). He then completed a cardiology fellowship at the University of Maryland and is currently working as a cardiologist in New Jersey.

May, 2001 -
December, 2001

Mentor, Research Assistantship

➤ Pari Shaw, MD

Project:

“Rapid HIV Testing Among Women in Drug Treatment”

Progress:

Dr. Shaw worked with me while she was a medical student at Brown. She is currently a resident in Internal Medicine, Chicago, IL. She is currently a gastroenterologist at the Hospital of the University of Pennsylvania.

January, 2002 -
August, 2002

Mentor, Research Assistantship

➤ Carly Cenedella

Project:

“Comprehensive Testing for HIV and Other Sexually Transmitted Diseases, and Hepatitis B Vaccination Among Substance Users”

Progress:

Dr. Cenedella took time off from medical school at Brown to work on a research project and decide if she wanted to complete medical school. She is currently an anesthesiologist at the University of Virginia.

July, 2002 -
July, 2003

Mentor, Research Assistantship

➤ Heather Ryan

Project:

“Rapid HIV Testing Among Women in Drug Treatment”

Progress:

Heather worked with me after she graduated from Duke. She went on to complete medical school at the University of Connecticut and is currently an Emergency Room physician in Chicago.

May, 2003 -
May, 2004

Mentor, Summer Research Assistantship

➤ Basim Khan

Projects:

“Hepatitis B vaccination: A model for HIV Vaccine Delivery,”
“HIV Vaccine Development: Epitope Conformation Project”

Progress:

Basim worked with me upon his graduation from Brown. He then completed medical school at the University of California, Los Angeles School of Medicine and received his MPA from Harvard Kennedy School. He is currently a primary care physician at the Alexandria Neighborhood Health Services Center in Alexandria, VA, and is working to improve access to health care in northern Virginia.

June, 2003 -
July, 2004

Mentor, Research Assistantship

➤ Liran Raz, MD

Project:

“”

Progress:

Dr. Raz is currently an OB/GYN physician in New York, New York

May, 2003 -
July, 2004

Mentor, Research Assistantship

➤ Zaid Sergie

Project:

“HIV Vaccine Clinical Trials”

Progress:

I worked with Ziad before he went to Tufts to earn his MD/MBA. Dr. Sergie is currently an internist at New York University.

September, 2003 -
May, 2005

Mentor, Research Assistantship

➤ Nancy DeSousa

Project:

“Community Awareness: HIV Vaccine Clinical Trials”

Progress:

I worked with Nancy when she was an undergraduate at Brown University. She then went on to earn her MPH at University of North

Carolina, Chapel Hill, and is currently in a PhD program in Public Health at Emory.

July, 2004 -
January, 2006

Mentor, Research Assistantship

➤ Sara Tedeschi

Project:

“Attitudes Among Young Women and Their Parents Toward HIV and HPV Vaccines and Vaccine Trials”

Progress:

Sara worked with me upon her graduation from Brown. She started medical school in August, 2006. She spent time with Dr. Carmen Zorilla at the HVTN site in Puerto Rico prior to starting medical school. She received her MD from Vanderbilt University in Nashville, Tennessee, and is currently an Internal Medicine Resident at Brigham and Women’s Hospital.

November, 1998 -
July, 2006

Mentor

➤ Curt Beckwith, MD

Projects:

Med student: ID elective, 1998

Resident: “Missed opportunities for HIV screening: Patients diagnosed with HIV in Rhode Island hospital over a two-year period, 2002”

ID Fellow: Multiple Rapid HIV testing projects

Progress:

Brown University Medical School, MD, 1998

Internal Medicine Internship/Residency/ Chief Residency

Brown University, 1998-2003

Infectious Disease Fellow, Brown University, 2003-2005

Dr. Beckwith has completed his T32 fellowship and joined our faculty in July, 2006. He is currently an Associate Professor of Medicine.

July, 2005 -
June, 2007

Mentor

➤ Loida Bonney, MD

Project:

I was one of Dr. Bonney’s primary mentors for her T32 Research Fellowship. She studied HPV vaccination barriers and facilitators, in underserved communities

Progress:

Brown University Medical School, MD, 2001

Combined Internal Medicine/Pediatrics Residency, 2005

Dr. Bonney completed a T32 Research Fellow at The Miriam Hospital in June, 2007. Dr. Bonney is currently an Assistant Professor of Medicine at Emory University.

February, 2006 -
June, 2006

Mentor

➤ Skyla Hayes and Natasha Paige, The Met School Students

Project:

“High School Internship: Second Semester, Junior Year”

Progress:

Conducted The Met School Health Fair on May 1, 2006

Created an HPV vaccine information Brochure for The Met School students in June, 2006.

June, 2006 -
December 2007

Mentor

➤ Kaitlin (Lemei) Thein, Research Assistant, Brown University

Project:

“Barriers to Minority Enrollment in HIV Clinical Trials”

Progress:

Kaitlin worked with me while an undergraduate at Brown, and she is currently at the Warren Alpert Medical School of Brown University.

Dr. Thein graduated from Brown in 2012 and is currently a pediatrics resident at UCSF.

September, 2006 -
May, 2007

Mentor

➤ Madhavi Parekh, Research Assistant, Brown Medical School

Project:

Assisted in the study of: “Willingness to Participate in HPV and HIV Clinical Trials Among Young Women, Adolescents, and Their Parents”

Progress:

Dr. Parekh completed an Internal Medicine Residency at Columbia University and is currently a Postdoctoral Clinical Fellow at Columbia.

September, 2006 -
June, 2008

Mentor

➤ Chia-Ching Wang, T32 Fellow

Project:

“Antiretroviral Adherence and Understanding of the Term ‘Undetectable Viral Load’ Among HIV Infected Persons With Well-Controlled HIV Disease”

Dr. Wang is also a Co-Investigator on: A Study of a Multivalent Human Papillomavirus (HPV) Vaccine Compared with GARDASIL® in 16- to 26-Year-Old Women HIV Vaccine Study (Merck 501-001)

Progress:

Dr. Wang completed her T32 fellowship in June, 2008. She completed the Internal Medicine Residency Program, The Warren Alpert Medical

School of Brown University, Lifespan, and will begin a fellowship in Hematology/Oncology next year.

2009 -

Mentor

➤ Heidi Elsa Larson

Project:

“Decisional Balance for Condom Use and Temptations for Unprotected Sex Among Gay and Bisexual Men”

Progress:

Elsa is currently a PhD candidate at the University of Rhode Island.

2011 -

Mentor

➤ Jacob van den Berg

Project:

1. "The Impact of Food Insecurity and Nutritional Status on HIV-Risk."

2. "HPV Vaccination among Young Men who have Sex with Men"

Progress:

Dr. van den Berg is working as an Assistant Professor of Medicine under Dr. Lally's mentorship. His broad area of interest is HIV prevention among men who have sex with men.

Date of Birth: September 19, 1967
Place of Birth: Providence, RI
Citizenship: United States
Home Address: 22 Mashie Road
Cumberland, RI 02864